Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity

• Main Authors: Darwish, S. (Author), Erdmann, F. (Author), Ghazy, E. (Author), Heimburg, T. (Author), Herp, D. (Author), Jung, M. (Author), Oehme, I. (Author), Ridinger, J. (Author), Robaa, D. (Author), Romier, C. (Author), Salem-Altintas, R. (Author), Schmidt, M. (Author), Schmidtkunz, K. (Author), Sippl, W. (Author), Zeyen, P. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: HDAC8; histone deacetylases (HDACs); neuroblastoma; proteolysis targeting chimera (PROTAC); synthesis
• Online Access: View Fulltext in Publisher

 In addition to involvement in epigenetic gene regulation, histone deacetylases (HDACs) regulate multiple cellular processes through mediating the activity of non-histone protein substrates. The knockdown of HDAC8 isozyme is associated with the inhibition of cell proliferation and apoptosis enhancement in several cancer cell lines. As shown in several studies, HDAC8 can be considered a potential target in the treatment of cancer forms such as childhood neuroblastoma. The present work describes the development of proteolysis targeting chimeras (PROTACs) of HDAC8 based on substituted benzhydroxamic acids previously reported as potent and selective HDAC8 inhibitors. Within this study, we investigated the HDAC8-degrading profiles of the synthesized PROTACs and their effect on the proliferation of neuroblastoma cells. The combination of in vitro screening and cellular testing demonstrated selective HDAC8 PROTACs that show anti-neuroblastoma activity in cells. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.